In 2022, Reshma Kewalramani earned $15.86M in total compensation at Vertex Pharmaceuticals, including $1.40M salary, $3.78M bonus and $10.64M in stock. Most recently acquired 19,015 shares in Feb 2025. Currently holds stock worth $54.74M. 5+ years at the helm of Vertex Pharmaceuticals.
Compensation History
Annual executive compensation data for Reshma Kewalramani, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$15.86M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Salary
$1.40MBoard Justification
The compensation philosophy aims to attract, retain, and motivate high-caliber executives, aligning their interests with those of shareholders and linking compensation to performance metrics.
Bonus
$3.78MBoard Justification
The bonus is based on company performance factors and individual performance factors, with a target cash bonus of 120% of base salary and a company performance factor of 145% for 2022.
Other Compensation
$43.06KBoard Justification
Other compensation includes contributions to the 401(k) plan, life insurance premiums, and matching gifts to charities.
Restricted Stock
Board Justification
The stock awards consist of performance-based RSUs and time-based RSUs that vested in 2022, reflecting the company's performance in the previous year.
Performance Metrics
The performance metrics for determining compensation include CF net product revenues and individual performance ratings.
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
CEO of Vertex Pharmaceuticals for
5 years 8 months (Apr 2020 - Present)
Previous Experience
Unknown
Other Vertex Pharmaceuticals CEOs
Holdings
Track Reshma Kewalramani's stock holdings and portfolio value over time.
Total Stock Sold
$61.05M
$61.05M
158,350 VRTX shares
What if they kept their stock?
If Reshma Kewalramani didn't sell their stock, today they would have:
Extra VRTX158,350 shares worth $72.41M.
This is 18.61% and $11.36M more than what they got when they sold the stock.
Insider Trading
Reshma Kewalramani's recent stock transactions, purchases, and sales filed with the SEC.
19,015 shares
VRTX
Feb 12, 2025
Received
49,446 shares
VRTX
Feb 4, 2025
Received
$7.83M
VRTX at $515.00/share
Nov 8, 2024
Sale
$7.68M
VRTX at $505.00/share
Jul 30, 2024
Sale
$7.56M
VRTX at $497.00/share
Jul 22, 2024
Sale
$715.21K
VRTX at $457.00/share
May 24, 2024
Sale
$6.80M
VRTX at $447.00/share
May 20, 2024
Sale
61,815 shares
VRTX
Feb 6, 2024
Received
$6.97M
VRTX at $407.00/share
Dec 15, 2023
Sale
$2.02M
VRTX at $397.00/share
Dec 13, 2023
Sale
Rivals
Compare Reshma Kewalramani with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Sundar Pichai
CEO of Alphabet Inc.
2024 Compensation
Stock
$51.70M
Salary
$2.02M
Bonus
$0.00
Other
$8.30M
Total Holdings
$399.66M
Andrew R. Jassy
CEO of Amazon
2024 Compensation
Stock
$38.48M
Salary
$365.00K
Bonus
$0.00
Other
$1.23M
Total Holdings
$2.14M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
David A. Ricks
CEO of Eli Lilly
2024 Compensation
Stock
$0.00
Salary
$1.69M
Bonus
$5.71M
Other
$351.69K
Total Holdings
$468.86M